Accepted Articles                   Back to the articles list | Back to browse issues page


XML Print


1- Assistant Professor of Physiology Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Researcher at Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
2- Research Assistant Professor of Physiology at Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran.
3- Assistant Professor of Respiratory Medicine, Collage of Medicine, University of Sulaimani, Sulaimani, Iraq.
4- Medical Student at School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Researcher at Student Research Committee, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
5- Research Assistant Professor of Anatomical Sciences at Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran. Researcher at Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran.
6- Medical Student at School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Researcher at Physiology Research Centre, Iran University of Medical Sciences, Tehran, Iran.
7- Professor of Biostatistics, Department of Epidemiology and Biostatistics School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:  
Objective: The present systematic review and meta-analysis intends to conduct a comprehensive and complete search in electronic resources to investigate the role of administrating ChABC in improving complications following SCI.
Methods: Medline, Embase, Scopus and Web of sciences were searched until the end of 2019. Two independent reviewers assessed the studies conducted on rats and mice and summarized the data. Using STATA 14.0 program, the findings were reported as pooled standardized mean differences (SMD) with 95% confidence intervals (CI).
Results: 34 pre-clinical studies were included. ChABC administration generally improves locomotion recovery after SCI (SMD = 0.90; 95% CI: 0.61 to 1.20; p <0.001). Subgroup analysis showed that differences in SCI model (p = 0.732), severity of injury (p = 0.821), number of ChABC administration (p = 0.092), blinding status (p = 0.294), use of different locomotor score (p = 0.567) and follow up duration (p = 0.750) have no effect on the efficacy of ChABC treatment.
Conclusion: The findings of the present study showed that prescribing ChABC has a moderate effect in the improvement of locomotion after SCI in mice and rats. However, this moderate effect introduces ChABC as an adjuvant therapy and not as a primary therapy.
Type of Study: Review | Subject: Clinical Neuroscience
Received: 2021/01/23 | Accepted: 2021/06/12

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.